- Record: found
- Abstract: found
- Article: not found
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Jim Cassidy
1 ,
Stephen Clarke ,
Eduardo Díaz-Rubio ,
Werner Scheithauer ,
Arie Figer ,
Ralph Wong ,
Sheryl Koski ,
Mikhail Lichinitser ,
Tsai-Shen Yang ,
Fernando Rivera ,
Felix Couture ,
Florin Sirzén ,
Leonard Saltz
Apr 20 2008
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate whether capecitabine plus oxaliplatin (XELOX) is noninferior to fluorouracil. folinic acid, and oxaliplatin (FOLFOX-4) as first-line therapy in metastatic colorectal cancer (MCRC).